In this review, we discuss how targeting CDK9 may help overcome the challenges in treating glioblastomas by modulating not only transcription but also tumor cell metabolism, DNA damage repair, epigenetics, and the immune response. This evidence concerns the gene CDK9 and glioblastoma.